Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting

Journal of Clinical Psychopharmacology

Volumn 32, Issue 2, 2012, Pages 207-217

  Yap, Kevin Yi Lwern ^a,b   Low, Xiu Hui ^a   Chui, Wai Keung ^a   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Anxiety descriptors; Chemotherapy induced nausea and vomiting; Clinical CINV end points; Principal component analysis; Principal variables

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; OXALIPLATIN;

ADULT; AIRWAY OBSTRUCTION; ANXIETY; ARTICLE; ASIAN; BECK ANXIETY INVENTORY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLD SWEAT; DIGESTIVE SYSTEM CANCER; DYING; DYSPNEA; FAINTNESS; FEAR; FEMALE; HEAD AND NECK CANCER; HOT FLUSH; HUMAN; INDIGESTION; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; NAUSEA AND VOMITING; NERVOUSNESS; OBSERVATIONAL STUDY; PARESTHESIA; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATE ANXIETY; TREATMENT RESPONSE; UNSTEADINESS;

EID: 84984578626     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31824888a1     Document Type: Article

References (32)

1. Stieler JM, Reichardt P, Riess H, et al. Treatment options for chemotherapy-induced nausea and vomiting: current and future. Am J Cancer. 2003;2:15-26. (Pubitemid 37047240)
2. Molassiotis A, Yam BMC, Yung H, et al. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer. 2002; 10:139-145. (Pubitemid 36056310)
3. Shih V, Wan HS, Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother. 2009;43:444-452.
4. Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer. 1989;64:1117-1122. (Pubitemid 19208867)
5. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4:191-196. (Pubitemid 29297482)
6. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J. 2008;14:85-93.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncologyi. Antiemesis v.1.2011. Updated November 30, 2010. Available at: http://www.nccn.org/professionals/physician-gls/PDF/antiemesis.pdf. Accessed January 10, 2011.
8. Roscoe JA, Morrow GR, Colagiuri B, et al. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer. 2010;18:869-876.
9. Bergkvist K,Wengström Y. Symptom experiences during chemotherapy treatment - with focus on nausea and vomiting. Eur J Oncol Nurs. 2006;10:21-29.
10. Spielberger CD, Gorsuch RL, Lushene RE. State-Trait Anxiety Inventory for Adults. Palo Alto, CA: Mind Garden; 1983.
11. Shek DT. The Chinese version of the State-Trait Anxiety Inventory: its relationship to different measures of psychological well-being. J Clin Psychol. 1993;49:349-358. (Pubitemid 23180602)
12. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893-897. (Pubitemid 19008360)
13. Luo N, Fones CS-L, Thumboo J, et al. Factors influencing health-related quality of life of Asians with anxiety disorders in Singapore. Qual Life Res. 2004;13:557-565. (Pubitemid 38392284)
14. Beck AT, Steer RA. Relationship between the beck anxiety inventory and the Hamilton anxiety rating scale with anxious outpatients. J Anxiety Disord. 1991;5:213-223.
15. Steer RA, Ranieri WF, Beck AT, et al. Further evidence for the validity of the beck anxiety inventory with psychiatric outpatients. J Anxiety Disord. 1993;7:195-205. (Pubitemid 23256489)
16. Gralla RJ, de Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 2005;104:864-868. (Pubitemid 41113689)
17. Herrstedt J, Apornwirat W, Shaharyar A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol. 2009;27:5363-5369.
18. Arpornwirat W, Albert I, Hansen VL, et al. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer. 2009;115: 5807-5816.
19. Hesketh PJ, Younger J, Sanz-Altamira P, et al. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer. 2009;17:1065-1070.
20. Yeo W, Mo FK, Suen JJ, et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009;113:529-535.
21. Jordan K, Kinitz I, Voigt W, et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer. 2009;45:1184-1187.
22. Mueller F, Jordan K, Jahn P, et al. The NK-1 antagonist aprepitant (APR) in combination with granisetron and dexamethasone in high dose chemotherapy (HDC). Eur J Cancer Suppl. 2009;7:200-201 (abstract 3087).
23. Dunteman GH. Principal Components Analysis. 1st ed. Newbury Park, CA: Sage Publications, Inc.; 1989.
24. Chow E, Fan G, Hadi S, et al. Symptom clusters in cancer patients with brain metastases. Clin Oncol (R Coll Radiol). 2008; 20:76-82.
25. Hadi S, Fan G, Hird AE, et al. Symptom clusters in patients with cancer with metastatic bone pain. J Palliat Med. 2008;11:591-600. (Pubitemid 351630192)
26. Cengiz B, Kuruo?lu HR. Interpretation of the repetitive nerve stimulation test results using principal component analysis. Clin Neurophysiol. 2006;117:2073-2078. (Pubitemid 44247889)
27. Yarnold PR, Soltysik RC. Optimal data analysis: a general statistical analysis paradigm. Optimal Data Anal. 2010;1:10-22.
28. Yap KY-L, Yak XR, Shih V, et al. Application of unsupervised learning in clinical oncology practiceVexploring anxiety characteristics in chemotherapy-induced nausea and vomiting through principal variables. J Comput. 2010;2:163-171.
29. Al-Kandari NM, Jolliffe IT. Variable selection and interpretation of covariance principal components. Commun Stat Simul Comput. 2001;30:339-354.
30. Lim A. Nose cancer is no. 6 killer among men here. Straits Times. 2008; section Mind Your Body. Available at: http://www.asiaone.com/ Health/Men%2527s%2BMatters/Cancer%2BCentre/Story/ A1Story20080904-85762.html. Accessed January 10, 2011.
31. National Registry of Diseases Office. Singapore Cancer Registry report: trends in cancer incidence in Singapore 2003-2007. Updated May 8, 2009. Available at: http://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/ Cancer%20Trend%20Report%2003-07%20for%20web%20v2.pdf. Accessed January 10, 2011.
32. de Kok IM, Wong CS, Chia KS, et al. Gender differences in the trend of colorectal cancer incidence in Singapore, 1968-2002. Int J Colorectal Dis. 2008;23:461-467.